Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06728059 · ClinicalTrials.gov registry record · NA

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

A NA study of Type 1 Diabetes, sponsored by Sue Brown.

Recruiting
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT06728059 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Sue Brown. The registered enrollment target is 16 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06728059, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Sue Brown.

RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS\_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.

Conditions Studied

Interventions

  • DEVICE Automated Insulin Delivery Adaptive NETwork (AIDANET)
  • DEVICE AIDANET+ BPS_RL→AIDANET

Study Locations (1)

Virginia

  • University of Virginia Center for Diabetes Technology - Charlottesville

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-02-05
Est. Completion 2025-07-31
Phase NA

Sponsor

Sue Brown

6 total trials

What the Registry Record Tells You About NCT06728059

The ClinicalTrials.gov registry entry for NCT06728059 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Sue Brown, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Automated Insulin Delivery Adaptive NETwork (AIDANET) is the first listed.

NCT06728059 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT06728059 about?

NCT06728059 is a clinical study titled "Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm". A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS\_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.

What is the current status of trial NCT06728059?

This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-02-05. Estimated completion is 2025-07-31.

What conditions does trial NCT06728059 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT06728059?

The interventions under investigation include: Automated Insulin Delivery Adaptive NETwork (AIDANET) (DEVICE), AIDANET+ BPS_RL→AIDANET (DEVICE).

Who is sponsoring clinical trial NCT06728059?

This trial is sponsored by Sue Brown, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06728059 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.